Immunome Inc
NASDAQ:IMNM

Watchlist Manager
Immunome Inc Logo
Immunome Inc
NASDAQ:IMNM
Watchlist
Price: 23.6 USD 5.31%
Market Cap: 2.2B USD

Operating Margin

-2 137.1%
Current
Declining
by 1 120.1%
vs 3-y average of -1 017%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2 137.1%
=
Operating Income
$-206.9m
/
Revenue
$9.7m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2 137.1%
=
Operating Income
$-206.9m
/
Revenue
$9.7m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Immunome Inc
NASDAQ:IMNM
2.2B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
372.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
175.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
153.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
76.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
40.8B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 14 112 companies
5th percentile
-2 137.1%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Immunome Inc
Glance View

Market Cap
2.2B USD
Industry
Biotechnology

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Exton, Pennsylvania and currently employs 39 full-time employees. The company went IPO on 2020-10-02. The firm's primary focus areas are oncology and infectious diseases. Its discovery platform identifies therapeutic antibodies and their targets by leveraging components of the immune system, memory B cells, from patients who have learned to fight off their disease. Its lead discovery programs include IMM-ONC-01 and IMM-BCP-01. IMM-ONC-01, is its lead oncology program, which is focused on IL-38. IMM-BCP-01, is its lead infectious disease discovery program with a focus on SARS-CoV-2, the virus that causes COVID-19. The firm is developing an antibody cocktail product candidate by identifying a combination of anti-viral antibodies produced by B cells from COVID-19 super-responders.

IMNM Intrinsic Value
7 USD
Overvaluation 70%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-2 137.1%
=
Operating Income
$-206.9m
/
Revenue
$9.7m
What is Immunome Inc's current Operating Margin?

The current Operating Margin for Immunome Inc is -2 137.1%, which is below its 3-year median of -1 017%.

How has Operating Margin changed over time?

Over the last 3 years, Immunome Inc’s Operating Margin has decreased from -1 259.3% to -2 137.1%. During this period, it reached a low of -2 137.1% on Oct 30, 2025 and a high of -204.9% on Dec 31, 2023.

Back to Top